Thayer Elizabeth, Walsh Lindsay, Leung Katherine, Korets Sharmilee
Departments of Obstetrics and Gynecology, University of Massachusetts Chan Medical School and UMass Memorial Healthcare, 119 Belmont St, Worcester, MA 01605, USA.
University of Massachusetts Chan Medical School, 55 Lake Ave North, Worcester, MA 01655, USA.
Gynecol Oncol Rep. 2023 Feb;45:101140. doi: 10.1016/j.gore.2023.101140. Epub 2023 Jan 21.
The COVID-19 vaccine is known to instigate an inflammatory response that impacts cancer testing. We aimed to evaluate carbohydrate antigen 125 (CA-125) trends in gynecologic oncology patients in surveillance following COVID-19 vaccination to inform clinical practice.
This was a single institution retrospective study of patients who received a COVID-19 vaccine while undergoing surveillance of gynecologic cancers with serial serum CA-125 measurements. CA-125 levels from the three months before and after vaccination were included in analysis. Differences between mean and median pre- and post-vaccination CA-125 levels for each patient were calculated. The mean and median of these differences were calculated, as well as the distribution of change. Demographic and cancer-related variables were also recorded.
Twenty-six patients who received a COVID-19 vaccine and were followed with surveillance serum CA-125 levels were identified. The mean age was 68.2 years; 92 % received a two-vaccine series. Forty-six percent had endometrial cancer and 54 % had ovarian cancer. The mean change from pre- to post-vaccine mean CA-125 level was 0.16 (±7.17) U/mL and the median change from pre- to post-vaccine median CA-125 level was -0.30 (IQR 3.66) U/mL. The range in change from pre- to post-vaccine mean was -16.50 to 24.00 U/mL, with 73 % of patients between -4 and +4 U/mL.
We found no clinically significant change in CA-125 level after patients under surveillance for gynecologic cancers were vaccinated against COVID-19, suggesting that that the vaccine does not impact the utility of CA-125 as a tool to monitor disease in this population.
已知新冠病毒疫苗会引发炎症反应，影响癌症检测。我们旨在评估接种新冠病毒疫苗后接受监测的妇科肿瘤患者血清糖类抗原125（CA-125）水平的变化趋势，为临床实践提供参考。
这是一项单机构回顾性研究，研究对象为在接受妇科癌症监测期间接受新冠病毒疫苗接种且进行了系列血清CA-125检测的患者。分析中纳入了接种疫苗前三个月和接种后三个月的CA-125水平。计算了每位患者接种疫苗前后CA-125平均水平和中位数水平的差异。计算了这些差异的均值和中位数，以及变化分布情况。还记录了人口统计学和癌症相关变量。
确定了26例接种新冠病毒疫苗并接受血清CA-125水平监测的患者。平均年龄为68.2岁；92%接受了两剂疫苗接种。46%患有子宫内膜癌，54%患有卵巢癌。接种疫苗前后CA-125平均水平的平均变化为0.16（±7.17）U/mL，接种疫苗前后CA-125中位数水平的中位数变化为-0.30（四分位间距3.66）U/mL。接种疫苗前后平均水平的变化范围为-16.50至24.00 U/mL，73%的患者变化在-4至+4 U/mL之间。
我们发现，接受妇科癌症监测的患者接种新冠病毒疫苗后，CA-125水平无临床显著变化，这表明该疫苗不影响CA-125作为该人群疾病监测工具的效用。
